2011, Number 598
<< Back Next >>
Rev Med Cos Cen 2011; 68 (598)
Comparación entre el etinilestradiol-acetato de ciproterona vrs. Etinilestradiol-Drospirenona para el tratamiento del síndrome de ovario poliquístico
Cerdas VB
Language: Spanish
References: 23
Page: 287-293
PDF size: 1349.00 Kb.
ABSTRACT
Polycystic Ovary Syndrome (PCOS) is a metabolic problem for those who suffer, however, by the skin changes involved, it is also an aesthetic nuisance, social and cultural. As appropriate treatment may become a critical piece of sufferers. The therapy can be focused on treating the disorder and induce fertility in patients whose intention is to bear children, or on the other hand, control the disorder while seeking contraception.
REFERENCES
ACOG Practice Bulletin No. 108: Polycystic Ovary Syndrome. Obstetrics & Gynecology. 2009 Oct; 114(4):936-49.
ACOG practice bulletin. Polycycstic ovary syndrome. Number 41, December 2002. lnt Journal Gynaecology & Obstetrics. 2003 Mar; 80(3):335-48.
Aguirre González, C. y Campos Aguiar, J. La metformina en el síndrome de ovario poliquístico. Med. leg. Costa Rica. 2007 Sep; 24(2):123-135.
Azziz, R. Androgen excess is the key element in polycystic ovary syndrorne. Fertil Steril. 2003 August; 80(2):252-254.
Costello, M. y Eden, J. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril. 2003 Jan; 79(1):1-13.
Diamanti-Kandarakis, E. et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab. 2003 May; 88(5): 1927-32.
Dres. Kee J. Ong, Efstathios Theodoru, William Ledger. Long-term consequence of polycystic ovarian syndrome. Current Obstetrics & Gynaecology. 2006 Dec; 16(6)333-336.
Fernández-Morales Donald. Manifestaciones clínicas del síndrome del ovario poliquístico. Acta méd. costarric. 2005 Oct; 47(4): 180-185.
Flórez, J. Farmacología Humana. 3a edición. 2000. Editorial Masson, S.A.
Hernández Sampieri, R. y colaboradores. Metodología de la investigación. Segunda edición. 2002. Editorial McGraw-Hill Interamericana Editores S.A. de CV. Pp. 115-116.
Huber, J. et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contraecpt Reprod Health Care. 2000; 5:25-34.
Jayagopal, A. et al. The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 2002 Apr; 87(4): 1560-2.
Kacar, S. et al. Estrogen and Cyproterone Acetate Combination-Induced Autoimmune Hepatitis. J Clin Gastroenterol. 2002; 35(1):98-99.
Lüdicke, F. et aL Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 µg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001 Jul; 76(1):102-7.
Padmanabhan, Y. et al. Dynamics of bioactive follicle-stimulating hormone secretion in women with polycystic ovary syndrome: effects of estradiol and progesterone. Fertil Steril. 2001 May; 75(5):881-8.
Pineda Elia y De Alvarado Eva Luz. Metodología de la investigación. 3ra edición. 2008. Organización Panamericana de la Salud. Washington, D.C
Radosh, Lee. Drug Treatments for Polycystic Ovary Syndrome. Am Fam Physician. 2009 Apr15; 79(8):671-676.
Richardson, M. Current Perspectives in Polycystic Ovary Syndrome. Am Fam Physician. 2003; 68:697-704.
Sheldon, T. Dutch GPs warned against new contraceptive pill BMJ. 2002 Apr 13; 324(7342):869.
Shulman, L. Safety and efficacy of a new oral contraceptive containing drospirenona. J Reprod Med. 2002 Nov; 47(11 Suppl):981-4.
Taylor, A. et al. Diagnosis and treatment of polycystic ovary syndrome in adults. www.uptodate.com. 2003 Apr; 1-10.
Van Vloten, W. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis (suppl 4) 2002; 69:2-15.
Wooltorton, E. Diane-35 (cyproterone acetate): safety concerns. CMAJ. 2003 Feb; 168(4):455-456.